Please login to the form below

Not currently logged in
Email:
Password:

disease progression

This page shows the latest disease progression news and features for those working in and with pharma, biotech and healthcare.

Bluebird Bio reveals further encouraging data for CALD gene therapy

Bluebird Bio reveals further encouraging data for CALD gene therapy

Other potential complications include graft-versus-host (GvHD) disease, when the transplanted cells recognise the recipient’s cells as foreign and attack them. ... Out of the 32 treated patients, three did not or will not meet the primary efficacy

Latest news

More from news
Approximately 1 fully matching, plus 245 partially matching documents found.

Latest Intelligence

  • Detecting Alzheimer’s ahead of a cure Detecting Alzheimer’s ahead of a cure

    According to the study, the blood test is able to identify this protein 20 years before the symptoms of the disease start to present. ... Alzheimer’s R&D has had to diversify as companies and researchers become increasingly aware that the disease has a

  • 25 Women Leaders in UK Healthcare (part 2) 25 Women Leaders in UK Healthcare (part 2)

    applications in pharma and real-world ML/AI platforms for scalable disease diagnostics, progression and treatment. ... We’re going to work with the NHS to eliminate this disease in the UK.

  • The first, my last, my everything The first, my last, my everything

    In a widespread shift from volume to value, around 80% of molecules in development at present are in oncology or rare disease. ... In the past, industry has taken a traditional view of patient value, typically basing it on clinical outcomes and disease

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimer’s disease R&D?

    other factors, may act on disease progression or influence responses to drugs. ... And there is scope to improve the lives of Alzheimer’s patients without slowing the progression of the disease, for example by hitting targets that improve cognition.

  • Brain power: fresh approaches to Alzheimer’s drug discovery Brain power: fresh approaches to Alzheimer’s drug discovery

    Luc Truyen, Vice President, Neuroscience External Affairs at Janssen R&D said that failures in the field pointed towards a need to target Alzheimer’s disease earlier in its progression. ... Diseases include Alzheimer’s, dementia with Lewy bodies,

More from intelligence
Approximately 0 fully matching, plus 25 partially matching documents found.

Latest appointments

  • PatientsLikeMe names Jason Johnson as head of R&D PatientsLikeMe names Jason Johnson as head of R&D

    Johnson will lead the company's research, data science and informatics teams, which focus on analysing and merging patient-reported data and other data types to develop models of disease progression ... and generate new insights about disease, treatments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 16 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics